

Pharma Intellectual Property
Novartis Pharma AG



Parallel trade and transparency: empowering patients

Myrtha Hurtado Rivas
Head of Global Trademarks
[DATE]

A universal trend among consumers increasingly demanding transparency.

- A 2019 report of Label Insight and FMI showed that shoppers want to know exactly what a **food item** is made from, where it is sourced from, and manufacturers' business practices and ethical positions.
- «The State of **Fashion** 2019» reports a shift towards radical transparency; consumers increasingly worry about production and supply chain, including issues like labor and sustainable resourcing.
- In 2019, the European Parliament approved additional consumer protection rules, requiring **online marketplaces** to ensure that consumers can identify from whom they are buying goods or services.
- In 2018, the WHO adopted a resolution encouraging countries to improve transparency about available **medicines**, patent status and pricing.

Transparency increases the accountability of manufacturers, and can facilitate responsive actions enabling consumers to make more informed decisions.

Transparency in parallel trade: do patients have a choice?

- Parallel traders exploit price differences among EEA states
- Due to different languages and regulations, imported products are modified:
 - by **re-labelling**;
 - by **re-boxing**; and/or
 - by **re-branding**
- Many parallel traders prefer re-boxing and try to market products in their own packaging.

This is not always known to patients, who may be unaware of parallel trade.



-  Typical countries of **importation**
-  Typical countries of **exportation**

Not all are parallel imports are equally easily recognizable



Here:
EXFORGE 10/160 mg
re-boxed imports into
Germany

Differences include:

- Type of packaging (white vs. design copy)
- Colors used
- Box sizes
- Font types and sizes
- Use of ®

One step further: some parallel traders try to appear as brand owner



1. Re-labeled original packaging

- Novartis branding with house marks
- Easily recognizable as import due to label on back of the packaging



2. Re-boxed product (NOT ACCEPTED)

- Addition of «Fisher Farma» logo
- Implies association between ENTRESTO and Fisher Farma

Another step further: re-branded generics

Belgian parallel traders buy **Sandoz generics** and re-sell them using **Innovative Medicines brands**.

- Payers are charged originator prices for generic products.
- High profit margins: re-selling prices are 10-30x the original price (usual margin for parallel traders around 20%).

Court decisions at the Brussels Commercial Court have been inconsistent; matter is now pending before the **CJEU**.



Right: «Letrozol Sandoz» appearing under «FEMARA» sticker on blister

Patients have a legitimate interest in identifying parallel imports

Re-packaging can conceal parallel imports and limit patients' ability to make an informed decision.

- Parallel trade occurs outside of the manufacturer's authorized supply chain.
- Re-packaging activities are a significant interference with product integrity.
- There are instances in which counterfeits were sold to parallel traders.

Patients should be empowered to make a decision in accordance with their personal preferences.

- Re-labeling is more transparent, as parallel imports can be easily identified.
- Severe interferences with product integrity should be complemented by rules enabling an easy identification of parallel imports.

The Falsified Medicines Directive (FMD): background and objective

In 2019, the FMD came into force, requiring all medicines to contain «**anti-tampering devices**» (ATD). Several parallel traders interpret this to **justify re-boxing of all products** into own, new outer packaging.

- Parallel traders claim that this is because they damage the original ATD when opening the packaging to replace the patient information leaflet.
- Coincidentally, this would allow parallel traders to standardize packaging procedures, substantially decrease operational costs and increase profits.

Cases about how parallel traders can re-label products in compliance with the FMD are currently pending before the CJEU.

Re-labeling in compliance with the FMD: examples and advantages

- The FMD allows safety features to be replaced by «equivalent» features.
- ATDs simply need to be functional; it does not mean that signs of the prior ATD must not be visible.
- It just needs to be understood by whom the new ATDs were affixed.

This way, patients can see that a product was imported and by whom it was modified.

This level of transparency cannot be reached through re-boxing.




Left: ATDs with parallel traders' company names or logos
Right: re-labeled packaging with parallel trader's silver ATD

Parallel trade and transparency: summary

- Consumers and patients demand transparency to enable them to make their own, personal choices.
- Parallel traded products have deficiencies regarding transparency, especially if products are re-boxed or re-branded.
- Parallel traders favor that conduct due to its commercial appeal: re-boxing can save costs, and re-branding allows for a different positioning in the market.

A restrictive approach to significant interferences with products is in the interest of patients, payers, and businesses.



Thank you